Press releases

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

January 13, 2022

STOCKHOLM — January 13, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...

Read more

Oncopeptides announces year-end cash 2021

Regulatory

January 5, 2022

STOCKHOLM — January 5, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today a...

Read more